On this week’s episode, we chat with Gabriel Levin, gynecologic oncologist at the McGill University Health Centre, and director of oncology at CureLab Oncology Inc., about elanagen, a promising therapeutic advance for women with platinum-resistant ovarian cancer; Eden Ben, CEO of Amorphical, about nano-amorphous mineral therapeutics inspired by blue crayfish; and Hans Schambye, CEO of BOOST Pharma, a company making progress in the battle with brittle bone disease.
Times:
03:36 Amorphical
26:26 CureLab Oncology
43:31 BOOST Pharma
CureLab Oncology
CureLab Oncology Inc. is a clinical-stage biotechnology company headquartered in the greater Boston area. The company is focused on developing safer, more effective treatments for solid tumours and inflammatory conditions.
CureLab’s lead programme, Elenagen, is an investigational DNA therapy consisting of a plasmid encoding the human protein p62/SQSTM1. In clinical studies conducted outside the US, Elenagen demonstrated a strong safety profile and statistically significant clinical benefit when combined with chemotherapy, along with evidence of immune activation and mitigation of chronic inflammation.
Amorphical
Amorphical is a biopharma company advancing a novel class of nano-amorphous mineral therapeutics, inspired by the blue crayfish.
Amorphical’s proprietary nano-amorphous calcium carbonate (ACC) agent demonstrates a unique mechanism: targeting and neutralizing the acidic microenvironments associated with inflammation and tumours.
The novel pH-modulating approach is already showing traction in a phase 2 FDA trial for hypoparathyroidism and the company recently reported positive data in a Crohn’s disease trial, with other programmes in pancreatic cancer.
BOOST
BOOST Pharma is BOOST Pharma was founded based on science from Karolinska Institutet, Sweden, a world-leader in cell therapy research. BOOST Pharma is developing a cell therapy treatment, BT-101, a cell therapy for osteogenesis imperfecta, also known as brittle bone disease, using mesenchymal stem cells.
BT-101 has demonstrated more than 70% fracture reduction in year one and about 78% in year two during phase I/II trials. The company is now gearing up for phase III paediatric trials with the more severe forms of OI (Types III and IV), aiming to move beyond the usual supportive care model and into potentially disease‑modifying territory.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com